Protocols

UK biotech sees boost in biotech fundraising so far this year; ChemoCentryx kills plans for stock offer

BIA and Informa Pharma Intelligence reported Friday that the UK biotech industry saw $2.05 billion in new fundraising in the first 8 months of this year — more than all of last year. That figure adds venture rounds with IPOs and follow-ons. 

ChemoCentryx $CCXI is cancelling plans for a new offering to raise cash. The Mountain View, CA-based biotech says that “the company believes that culmination of terms representing the best interests of its stockholders is not to be achieved at the current time.”


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->